Abstract
Primary and metastatic tumours in the central nervous system have generally been refractory to successful treatment with chemotherapeutic agents. A few drugs have the capacity for traversing the blood-brain barrier by virtue of their lipid solubility. These include the nitrosoureas and corticosteroids. The nitrosoureas have been used extensively in the treatment of primary brain tumours with only marginal benefit, nor have they been found to be successful as prophylactic agents against central nervous system leukaemia. To date, few chemotherapeutic agents have been found to be effective against primary brain tumours. In comparison to primary neoplastic disease there is a significantly larger number of patients with metastases to the CNS. The most common tumours include carcinoma of the lung, breast, melanoma, and lymphoma. This complication has appeared more commonly as the therapy for systemic disease as chemotherapy improves the longterm disease-free survival. The incidence of late central nervous system metastases has been noted in tunours in which it was previously a rare complication. This is especially true in testicular tumours, sarcomas, and more recently, ovarian carcinoma (Mayer et al., 1978).
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Similar content being viewed by others
References
Bunn, P. A., Jr., Schein, P. S., Banks, P. M. and DeVita, V. T. (1976). Central nervous system complications in patients with diffuse histiocytic and undifferentiated lymphoma: leukemia revisited. Blood, 47, 3.
DeVita, V. T., Chabner, B., Hubbard, S. P., Canellos, G. P., Schein, P. and Young, R. C. (1975). Advanced diffuse histiocytic lymphoma, a potentially curable disease. Lancet i, 248.
Fisher, R. I., DeVita, V. T., Johnson, B. L., Simon, R. and Young, R. C. (1977). Prognostic factors for advanced diffuse histiocytic lymphoma following treatment with combination chemotherapy. Am. J. Med. 63, 177.
Gutin, P. H., Weiss, H. D., Wiernik, P. H. and Walker, M. D. (1976). Intrathecal N,N′,N″-triethylenethiophosphoramide [thio-tepa (NSC 6396)] in the treatment of malignant meningeal disease. Cancer, 38, 1471.
Ho, D. and Frei, E. (1971). Clinical pharmacology of 1-β-D-arabinofuranosyl cytosine. Clin. Pharmac. Ther. 12, 944.
Mayer, R. J., Berkowitz, R. W. and Griffiths, C. T. (1978). Central nervous system involvement by ovarian carcinoma. Cancer, 41, 776.
Okabayashi, T., Mihara, S., Repke, D. and Moffatt, J. (1977). A radioimmunoassay for 1-β-D-arabinofuranosyl cytosine. Cancer Res., 37, 619.
Rodriguez, V., Cabanillas, F., Burgess, M. A., McKelvey, E. M., Valdivieso, M., Bodey, G. P. and Freireich, E. J. (1977). Combination chemotherapy (“CHOPBleo”) in advanced (Non-Hodgkin) malignant lymphoma. Blood, 49, 325.
Schein, P. S., DeVita, V. T., Hubbard, S., Chabner, B. A., Canellos, G. P., Berard, C. and Young, R. C. (1976). Bleomycin, Adriamycin, Cyclophosphamide, Vincristine, and Prednisone (BACOP) combination chemotherapy in the treatment of advanced diffuse histiocytic lymphoma. Ann. intern. Med., 85, 417.
Shapiro, W. R., Young, D. F. and Mehta, B. M. (1975). Methotrexate: distribution in cerebrospinal fluid after intravenous ventricular and lumbar injections. New Eng. J. Med., 293, 161.
Skarin, A., Canellos, G. P., Rosenthal, D., Moloney, W. and Frei, E. (1978). Therapy of unfavorable histology non-Hodgkin’s lymphoma (NHL) with high dose Methotrexate and citrovorum factor rescue (MTX/CF), Bleomycin, Adria- mycin (A), Cyclophosphamide (C), OncovinR (0), and Decadron (D) (MBACOD). Proc. Am. Soc. Clin. Onc., 19, 400.
Skarin, A. T., Rosenthal, D. S., Moloney, W. C. and Frei, E. (1977). Combination chemotherapy of advanced non-Hodgkin lymphoma with Bleomycin, Adriamycin, Cyclophosphamide, Vincristine, and Prednisone (BACOP). Blood, 49, 759.
Skarin, A. T., Zuckerman, K. S., Pitman, S. W., Moloney, W., Frei, E. and Canellos, G. P. (1977). High-dose Methotrexate with folinic acid in the treatment of advanced non-Hodgkin lymphoma including CNS involvement. Blood, 50, 1039.
Tattersall, M. H. N., Parker, L. M., Pitman, S. W. and Frei, E. (1975). Clinical pharmacology of high-dose Methotrexate (NCS-740). Cancer Chemother. Rep., 6, 25.
Wang, J. J. and Pratt, C. B. (1970). Intrathecal arabinosyl cytosine in meningeal leukemia. Cancer, 25, 531.
Weinstein, H., Griffin, T., Cohen, H., Propper, R. and Sallan, S. (1978). Pharmacology of cytosine arabinoside. Proc. Am. Ass. Cancer Res., 19, 157.
Editor information
Editors and Affiliations
Copyright information
© 1979 G. P. Canellos, A. T. Skarin, T. Ervin and H. Weinstein
About this chapter
Cite this chapter
Canellos, G.P., Skarin, A.T., Ervin, T., Weinstein, H. (1979). A Chemotherapeutic Approach to CNS Lymphoma and Leukaemia by the Systemic Administration of High Doses of Antimetabolites. In: Whitehouse, J.M.A., Kay, H.E.M. (eds) CNS Complications of Malignant Disease. Palgrave Macmillan, London. https://doi.org/10.1007/978-1-349-04285-2_13
Download citation
DOI: https://doi.org/10.1007/978-1-349-04285-2_13
Publisher Name: Palgrave Macmillan, London
Print ISBN: 978-1-349-04287-6
Online ISBN: 978-1-349-04285-2
eBook Packages: MedicineMedicine (R0)